Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

US Market Report for Rheumatoid Arthritis Immunology Drugs 2018 - MedCore

Reportlinker
Posted on: 07 Nov 17
US Market Report for Rheumatoid Arthritis Immunology Drugs 2018 - MedCore

PR Newswire

NEW YORK, Nov. 6, 2017

NEW YORK, Nov. 6, 2017 /PRNewswire/ --


General Report Contents
- Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends



Read the full report: https://www.reportlinker.com/p05175235


- Market Drivers & Limiters for each chapter segment
- Competitive Analysis for each chapter segment
- Section on recent mergers & acquisitions

Current treatments of RA aim to relieve the symptoms of the disease and regain the maximum functionality of the damaged joint. There is no cure for rheumatoid arthritis. The initial treatment option is disease-modifying antirheumatic drugs, also known as DMARDs.

DMARDs are a group of medications commonly used in patients with rheumatoid arthritis. Some of these drugs are also used in treating other conditions such as ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus. DMARDs work to reduce pain and inflammation, to prevent or minimize joint damage. They take effect over months and are not designed to provide immediate relief of symptoms.
DMARDs can be prescribed along with nonsteroidal anti-inflammatory drugs and/or low-dose corticosteroids. Common DMARDs include methotrexate (Rheumatrex, Trexall, Otrexup, and Rasuvo), leflunomide (Arava), hydroxychloroquine (Plaquenil) and sulfasalazine (Azulfidine).

Patients in more severe stages of the disease may need biologic response modifiers. These medications can block immune system chemical signals that lead to inflammation and joint damage. The biologic drugs include ORENCIA® (abatacept), HUMIRA® (adalimumab), Kineret® (Anakinra), CIMZIA® (certolizumab), ENBREL® (etanercept), SIMPONI® (golimumab), REMICADE® (infliximab), Rituxan® and MabThera® (rituximab) and Actemra® (tocilizumab).

Abstract
Rheumatoid arthritis (RA) is a chronic systemic disease affecting joints, connective tissue, muscles, tendons and fibrous tissue. It is a chronic inflammatory disorder that occurs when the immune system attacks the lining of the membranes that surround joints, leading to a painful swelling and destroys the cartilage and bone, resulting in permanent joint deformity.

RA is one of the most disabling types of arthritis that causes joint pain, stiffness and decreased movement of the joints. Small joints in the hands and feet are most commonly affected. Sometimes RA can affect other organs, such as eyes, skin or even heart or lungs.

Scope
2014-2024

Read the full report: https://www.reportlinker.com/p05175235

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

https://www.reportlinker.com


__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/us-market-report-for-rheumatoid-arthritis-immunology-drugs-2018---medcore-300550603.html

SOURCE Reportlinker

PR Newswire
www.prnewswire.com

Last updated on: 07/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.